Compare Mondaycom Ltd (MNDY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs BIO-TECHNE Corp — how do they compare? Mondaycom Ltd trades at $87.13 (market cap $3.76B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 3× Mondaycom Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| MNDY | TECH | |
|---|---|---|
Market Cap | $3.76B | $11.24B |
Sector | Technology | Health |
52-Week High | $219.15 | $72.29 |
52-Week Low | $58.81 | $43.31 |
Enterprise Value | $2.73B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $93.13, up 6.35% with strong technical momentum and bullish moving average signals. The company delivered another earnings beat with Q2 2026 EPS of $1.48 versus $1.14 expected, though recent news highlights investor concerns over Q3 revenue guidance. Fundamentals show robust 89% gross margins and consistent profitability, while valuation ratios remain elevated with a P/E of 38.85.
The outlook remains positive with 76% analyst buy ratings and a $120 consensus target, representing 29% upside potential. Key risks include slower revenue growth guidance and competitive pressures in the SaaS sector. The stock's recent volatility reflects the tension between strong current performance and forward-looking concerns about growth sustainability.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
